Abstract
PurposeGlioblastoma is an aggressive malignant cancer of the central nervous system, with disease progression associated with deterioration of neurocognitive function and quality of life (QoL). As such, maintenance of QoL is an important treatment goal. This analysis presents time to deterioration (TtD) of QoL in patients with recurrent glioblastoma receiving Asunercept plus reirradiation (rRT) or rRT alone.MethodsData from patients with a baseline and ≥ 1 post-baseline QoL assessment were included in this analysis. TtD was defined as the time from randomisation to the first deterioration in the EORTC QLQ-C15, PAL EORTC QLQ-BN20 and Medical Research Council (MRC)-Neurological status. Deterioration was defined as a decrease of ≥ 10 points from baseline in the QLQ-C15 PAL overall QoL and functioning scales, an increase of ≥ 10 points from baseline in the QLQ-C15 PAL fatigue scale and the QLQ-BN20 total sum of score, and a rating of “Worse” in the MRC-Neurological status. Patients without a deterioration were censored at the last QoL assessment. Kaplan–Meier estimates were used to describe TtD and treatment groups (Asunercept + rRT or rRT alone) were compared using the log-rank test.ResultsTreatment with Asunercept + rRT was associated with significant improvement of TtD compared with rRT alone for QLQ-CL15 PAL overall QoL and physical functioning, and MRC Neurological Status (p ≤ 0.05). In the Asunercept + rRT group, QoL was maintained beyond progresison of disease (PoD).ConclusionTreatment with Asunercept plus rRT significantly prolongs TtD and maintains QoL versus rRT alone in recurrent glioblastoma patients.
Highlights
Glioblastoma (GB) is the most aggressive malignant cancer of the central nervous system and accounts for > 60% of adult brain tumours [1]
Treatment with Asunercept + rRT was associated with significant improvement of time to deterioration (TtD) compared with rRT alone for QLQ-CL15 PAL overall quality of life (QoL) and physical functioning, and Medical Research Council (MRC) Neurological Status (p ≤ 0.05)
Group, QoL was maintained beyond progresison of disease (PoD)
Summary
Glioblastoma (GB) is the most aggressive malignant cancer of the central nervous system and accounts for > 60% of adult brain tumours [1]. No treatment standard exists for GB at progression, but available therapeutic strategies include reoperation, reirradiation (rRT), alkylating chemotherapy with temozolomide or nitrosoureas (such as lomustine), bevacizumab, and experimental agents used within clinical trials [5,6,7,8,9]. With the absence of standard therapy, enrolment into clinical trials is recommended by guidelines as the preferred treatment approach [6,7,8, 10, 11]. This highlights the urgent need for new innovative approaches for the treatment of recurrent
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
